{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:05:19Z","timestamp":1781089519255,"version":"3.54.1"},"reference-count":62,"publisher":"Informa UK Limited","issue":"1-2","funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2509003"],"award-info":[{"award-number":["2023YFC2509003"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Natural Science Funds for Distinguished Young Scholars","award":["82225039"],"award-info":[{"award-number":["82225039"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473545"],"award-info":[{"award-number":["82473545"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173448"],"award-info":[{"award-number":["82173448"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/14728214.2026.2655714","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:17:43Z","timestamp":1778649463000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Early investigational agents for the treatment of rosacea: drugs in phase II and III clinical development"],"prefix":"10.1080","volume":"31","author":[{"given":"Kejia","family":"Tian","sequence":"first","affiliation":[{"name":"Central South University","place":["Changsha, China"]},{"name":"Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, China"]},{"name":"Central South University","place":["Changsha, China"]},{"name":"Central South University","place":["Changsha, China"]},{"name":"Furong Laboratory","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Wang","sequence":"additional","affiliation":[{"name":"Central South University","place":["Changsha, China"]},{"name":"Central South University","place":["Changsha, China"]},{"name":"Central South University","place":["Changsha, China"]},{"name":"Furong Laboratory","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.037"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15122"},{"issue":"6","key":"e_1_3_4_6_1","first-page":"533","article-title":"Rosacea: common questions and answers","volume":"109","author":"Frazier W","year":"2024","unstructured":"Frazier W, Zemtsov RK, Ge Y. Rosacea: common questions and answers. Am Fam Physician. 2024;109(6):533\u2013542. PubMed PMID: 38905551; eng.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367994"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082153"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.11.001"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.116189"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.141"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013560"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113292"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111636"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.028"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.009"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000000644"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2022.2128334"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.077"},{"issue":"2","key":"e_1_3_4_20_1","first-page":"97","article-title":"Update on rosacea pathogenesis and correlation with medical therapeutic agents","volume":"78","author":"Del Rosso JQ","year":"2006","unstructured":"Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78(2):97\u2013100. PubMed PMID: 16983897; eng.","journal-title":"Cutis"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000197"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15155"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S427530"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.063"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.050"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.06.027"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15747"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.853"},{"issue":"7","key":"e_1_3_4_29_1","first-page":"28","article-title":"Topical a-agonist therapy for persistent facial erythema of rosacea and the addition of oxmetazoline to the treatment armamentarium: where are we now?","volume":"10","author":"Del Rosso JQ","year":"2017","unstructured":"Del Rosso JQ. Topical a-agonist therapy for persistent facial erythema of rosacea and the addition of oxmetazoline to the treatment armamentarium: where are we now? J Clin Aesthet Dermatol. 2017;10(7):28\u201332. PubMed PMID: 29104721; PubMed Central PMCID: PMCPMC5605221. eng.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.204"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402080"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.01.044"},{"key":"e_1_3_4_33_1","unstructured":"University WS. Evaluating use of topical imipramine and amitriptyline in reducing ultraviolet b light-induced redness in patients with rosacea. ClinicalTrialsgov. 2024 Aug 10."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07307-z"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.76.896.361"},{"key":"e_1_3_4_36_1","unstructured":"Dermatology Consulting Services P. Evaluation of the safety and efficacy of topical roflumilast cream in the treatment of facial papulopustular rosacea. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05278624"},{"key":"e_1_3_4_37_1","unstructured":"Sinai ISoMa M. PDE4 inhibition in seborrheic dermatitis and papulopustular rosacea. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06013371"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581819852325"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1693-0"},{"key":"e_1_3_4_40_1","unstructured":"BioMimetix JV L. Evaluation of topical application of BMX-010 in subjects with rosacea. National Library of Medicine; 2018 [updated 2022 Sep 28;2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03756389"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.0408"},{"key":"e_1_3_4_42_1","unstructured":"S.P.A. A. Safety efficacy and pharmacokinetics of rifaximin in patients with moderate-to-severe papulopustular rosacea. National Library of Medicine; 2021 [2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05150587"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S98091"},{"issue":"9","key":"e_1_3_4_44_1","first-page":"39","article-title":"Topical ivermectin: data supporting dual modes of action in rosacea","volume":"10","author":"Del Rosso JQ","year":"2017","unstructured":"Del Rosso JQ. Topical ivermectin: data supporting dual modes of action in rosacea. J Clin Aesthet Dermatol. 2017;10(9):39\u201342. PubMed PMID: 29515751; PubMed Central PMCID: PMCPMC5749619. eng.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_45_1","unstructured":"Insel Gruppe AG UHB. Potassium-titanyl phosphate (KTP) laser vs KTP laser and ivermectin cream for facial rosacea. KIR: National Library of Medicine; 2023 [updated 2024 Dec 06; 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06033352"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.03.031"},{"issue":"3","key":"e_1_3_4_47_1","first-page":"134","article-title":"Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 5: a guide on the management of rosacea","volume":"93","author":"Del Rosso JQ","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3):134\u2013138. PubMed PMID: 24738094; eng.","journal-title":"Cutis"},{"issue":"3","key":"e_1_3_4_48_1","first-page":"32","article-title":"Topical oxymetazoline hydrochloride cream 1% for the treatment of persistent facial erythema of rosacea in adults: a comprehensive review of current evidence","volume":"14","author":"Del Rosso JQ","year":"2021","unstructured":"Del Rosso JQ, Tanghetti E. Topical oxymetazoline hydrochloride cream 1% for the treatment of persistent facial erythema of rosacea in adults: a comprehensive review of current evidence. J Clin Aesthet Dermatol. 2021;14(3):32\u201337. PubMed PMID: 33841614; PubMed Central PMCID: PMCPMC8021401. eng.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_49_1","unstructured":"Inc. A. A clinical endpoint bioequivalence study of \u201coxymetazoline hydrochloride cream\u201d. National Library of Medicine; 2019 [cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03954444"},{"key":"e_1_3_4_50_1","unstructured":"LLC P. An evaluation of the reduction in erythema in adult patients with moderate to severe persistent facial erythema associated with rosacea. National Library of Medicine; 2017 [updated 2021 Nov 08; cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03352323"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15467"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.05.003"},{"key":"e_1_3_4_53_1","unstructured":"Maruho Co. L. Study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle. National Library of Medicine; 2015 [updated 2022 Aug 02; cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02576860"},{"key":"e_1_3_4_54_1","unstructured":"Maruho Co. L. Study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle2. National Library of Medicine; 2015 [updated 2022 Aug 02; cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02547441"},{"key":"e_1_3_4_55_1","unstructured":"Maruho Co. L. Study to evaluate the long-term safety of a once-daily omiganan topical gel. National Library of Medicine; 2015 [updated 2022 July 19; cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02576847"},{"key":"e_1_3_4_56_1","unstructured":"Inc. VT. A study (study 1) to evaluate the safety and efficacy of FMX103 1.5% topical minocycline foam in the treatment of facial papulopustular rosacea. National Library of Medicine; 2017 [updated 2021 Jan 29; cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03142451"},{"key":"e_1_3_4_57_1","unstructured":"Inc. VT. A study (study 2) to evaluate the safety and efficacy of FMX103 1.5% topical minocycline foam in the treatment of facial papulopustular rosacea. National Library of Medicine; 2020 [cited 2024 Aug 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04608500"},{"issue":"11","key":"e_1_3_4_58_1","first-page":"44","article-title":"Open-label extension study evaluating long-term safety and efficacy of FMX103 1.5% minocycline topical foam for the treatment of moderate-to-severe papulopustular rosacea","volume":"13","author":"Stein Gold L","year":"2020","unstructured":"Stein Gold L, Del Rosso JQ, Kircik L, et al. Open-label extension study evaluating long-term safety and efficacy of FMX103 1.5% minocycline topical foam for the treatment of moderate-to-severe papulopustular rosacea. J Clin Aesthet Dermatol. 2020;13(11):44\u201349. PubMed PMID: 33282103; PubMed Central PMCID: PMCPMC7716737. eng.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"10","key":"e_1_3_4_59_1","first-page":"41","article-title":"Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in papulopustular rosacea in elderly patients: post-hoc analysis of results from two randomized, phase III, vehicle-controlled trials","volume":"17","author":"Green LJ","year":"2024","unstructured":"Green LJ, Baldwin H, Sugarman J, et al. Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in papulopustular rosacea in elderly patients: post-hoc analysis of results from two randomized, phase III, vehicle-controlled trials. J Clin Aesthet Dermatol. 2024;17(10):41\u201344. PubMed PMID: 39445322; PubMed Central PMCID: PMCPMC11495165. eng.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"e_1_3_4_60_1","first-page":"34","article-title":"Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from two phase III, randomized, vehicle-controlled trials","volume":"16","author":"Bhatia ND","year":"2023","unstructured":"Bhatia ND, Werschler WP, Baldwin H, et al. Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from two phase III, randomized, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):34\u201340. PubMed PMID: 37636253; PubMed Central PMCID: PMCPMC10452484. eng.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"e_1_3_4_61_1","first-page":"27","article-title":"Long-term efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from an extension of two phase III, vehicle-controlled trials","volume":"16","author":"Werschler WP","year":"2023","unstructured":"Werschler WP, Sugarman J, Bhatia N, et al. Long-term efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from an extension of two phase III, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):27\u201333. PubMed PMID: 37636251; PubMed Central PMCID: PMCPMC10452482. eng.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.6542"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16300"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19732"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2655714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:33:21Z","timestamp":1781087601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2026.2655714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":62,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/14728214.2026.2655714"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2026.2655714","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}